MA1-24767

antibody from Invitrogen Antibodies

Targeting: HGF DFNB39, F-TCF, HGFB, HPTA, SF

Other assay (Supportive data in Antibodypedia)

Antibody Data

Product number

MA1-24767

Provider

Invitrogen Antibodies

Product name

HGF Monoclonal Antibody (24612.111)

Antibody type

Monoclonal

Antigen

Recombinant full-length protein

Description

Monoclonal Anti-Human HGF was tested for its ability to neutralize the bioactivity of rhHGF in a cell proliferation assay using 4MBr-5 cells, a monkey epithelial cell line responsive to HGF.

Antibody clone number

24612.111

Concentration

0.5 mg/mL

References

Submitted references

Non-canonical cMet regulation by vimentin mediates Plk1 inhibitor-induced apoptosis.

Singh R, Peng S, Viswanath P, Sambandam V, Shen L, Rao X, Fang B, Wang J, Johnson FM
EMBO molecular medicine 2019 May;11(5)

Other assay

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Figure EV5 Plk1 regulates vimentin phosphorylation, leading to integrin beta1-mediated cM et activation A Non-small-cell lung cancer cell lines were treated with 50 nM volasertib in serum-free medium for 24 h. HGF levels were measured in conditioned medium (upper). Data are means +- standard error of the mean from three independent experiments. Non-small-cell lung cancer cell lines were treated as indicated with 25 nM volasertib or 400 nM tepotinib for 24 h. Cells were then harvested, and lysates were immunoblotted for the indicated proteins (lower). B The indicated mesenchymal cell lines were incubated with 0.5 mug/mL HGF neutralizing antibody or 50 nM volasertib as indicated for 24 h and subjected to immunoblotting. C NSCLC cell line mRNA expression of vimentin ( VIM ) and integrin beta1 ( ITGB1 ) and epithelial-to-mesenchymal transition (EMT) scores were obtained from our previous study (22). Spearman's correlations of EMT score and mRNA expression of VIM and ITGB1 in NSCLC cell lines in vitro . D Calu6 and H1792 cell lines were transfected with 10 nM siRNA for 48 h and subsequently treated with 25 nM volasertib for 24 h as indicated. Cells were then harvested, and lysates were immunoblotted for the indicated proteins. E NSCLC cell lines were transfected with ITGB1 and Plk1 siRNA for 48 h. Cells were then harvested, and lysates were immunoblotted for the indicated proteins. F NSCLC cell lines were treated with volasertib in fibronectin-coated (5 mug/cm 2 for 30 min at room